SAN JOSE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (OTCQB: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, announced today its financial results for the quarter ended June 30, 2025. As of June 30, 2025, the Fund’s net assets were approximately $0.7 million, or $0.11 per share, compared with net assets of approximately $0.8 million, or $0.12 per share as of March 31, 2025. As of June 30, 2025, the Fund’s portfolio included public and private securities valued at approximately $0.7 million, or $0.10 per share, which includes approximately $0.07 per share in cash and cash equivalents. Portfolio Summary (as of 6/30/25)Investment Fair Value1, Fair Value per Share1,2Equity/Debt Investments $0.22 million $0.03Cash/Cash Equivalents $0.51...

280% increase in quarterly revenue with a strong start in its energy services and edge computing businesses puts the Company on plan to achieve guidance of $28M to $30M for the full year JACKSONVILLE, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) — Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT), a provider of adaptive, versatile and streamlined Edge Data Center (“EDC”) solutions and operational services for the deployment of “behind the meter” electrical power reported financial results for the second quarter (“Q2 2025”) ended June 30, 2025. In addition to the equivalent quarter revenue growth, consecutive quarterly revenue growth was more than 16% for a total of $10.7 million for the first six months, the highest revenue for that period in the Company’s history.Second Quarter 2025 and Recent Operational...

Expands senior leadership team and board of directors to support next phase of growth ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2025. Neal Goldman, Chairman of the Board, stated, “We are pleased with our revenue performance in the second quarter, delivering a 25% increase in revenue to $2.3 million, driven by strong international dental sales, which more than doubled year-over-year. We also maintained a strong gross margin of 70%, reflecting the benefits of our high-margin dental business and disciplined cost management. Equally important, we have significantly strengthened our...

Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the second quarter ended June 30, 2025, and provides an overview of recent and upcoming business highlights. “The second quarter of 2025 marked steady execution and progress on our key strategic initiatives:  clinical development of our radiotherapeutic and the advancement of our diagnostic platform technologies toward commercialization,” said Marc H. Hedrick, M.D., Plus Therapeutics President...

Raises $30 Million From Oversubscribed Offering and Eliminates Debt & Obligations VIRGINIA CITY, Nev., Aug. 14, 2025 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock,” “our,” and the “Company”), today announced its second quarter 2025 results, business updates and an updated 2025 business outlook. Recent Corporate Liquidity and Capital Resources EventsClosed the initial $20 Million of Series A Investment and completed the separation of Fuels into Bioleum Corporation; Raised $30 million in gross proceeds to fully fund and accelerate the commercialization of its R2v3/RIOS Responsible Recycling certified zero-landfill industry-scale solar panel recycling facilities, each capable of recycling over 3.3 million panels per year, and to eliminate debts and advance additional site selections and other key development initiatives; Paid...

~ Q2 Gross Margin Expansion, Cost Reductions, Strategic Transactions, and Diversified Revenue Initiatives Could Position Super League to Achieve Adjusted EBITDA Positive in Q4 ~ ~ Company Advances Key Financial Initiatives and Broadens Revenue Mix ~ SANTA MONICA, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Super League (Nasdaq: SLE), a leader in engaging audiences through playable media, content, and experiences within mobile games and the world’s largest immersive platforms, today released second quarter 2025 financial results. Super League Chief Executive Officer, Matt Edelman Commented: “Our second quarter marked a pivotal step forward for Super League as we streamlined our operations, executed key financial transactions, launched innovative partnerships, and re-aligned the company’s focus toward reaching sustainable profitability....

LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) — Nova LifeStyle, Inc. (NASDAQ: NVFY) (“Nova LifeStyle” or the “Company”) today announced its financial results for the second quarter ended June 30, 2025. Key Financial Highlights: Operating Results for the Three Months Ended June 30, 2025:Net sales for three months ended June 30, 2025 were $2.56 million, a decrease of 5% from $2.69 million in the same period of 2024. Gross profit was $1.28 million compared to $1.19 million in the same period of 2024. Net loss was ($289 thousand), compared to ($536 thousand) loss in the same period of 2024.Operating Results for the Six Months Ended June 30, 2025:Net sales for the six months ended June 30, 2025 were $5.19 million, an increase of 3% from $5.06 million in the same period 2024. Gross profit was $2.49 million, compared to $2.21 million...

POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported preliminary financial results for the second quarter ended June 30, 2025. Recent Business Highlights:Appointed Brandon Poe as Chief Financial Officer, a seasoned financial executive with experience across the healthcare sector Completed enrollment in a clinical trial evaluating BioREtain® Amnion Chorion for the treatment of diabetic foot ulcers, with a data readout expected in the fourth quarter 2025 Initiated expansion of the commercial organization including the hiring of direct representatives to access new sites of care Expanded the intellectual...

Second Quarter 2025 Revenues Totaled $3.3 Million, Driven by Continued Industry Recognition of Intellectual Property Portfolio CORSICANA, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) — Birchtech Corp. (TSX: BCHT) (OTCQB: BCHT) (“Birchtech” or the “Company”), a leader in specialty activated carbon technologies for sustainable air and water treatment, today reported financial results for the second quarter ended June 30, 2025. Key Second Quarter 2025 & Subsequent Operational HighlightsPending final judgment following the $57 million patent infringement verdict, from which the Company’s counsel requested $160 million inclusive of enhancements, interest and legal fees. Management provided revised guidance of air business revenues of at least $18 million in 2025 (excludes water treatment and judgments in defense...

TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the second quarter ended June 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business HighlightsUtilization of current TULSA-PRO® systems continues to grow, with “same store” procedure volumes up 10% sequentially from Q1-2025.The Company’s TULSA-PRO® qualified sales pipeline is also growing, and now stands at 80 new systems being classified within one of the “Verify,...